What the MDR Regulation entails for manufacturers, importers and distributors in Switzerland
“Compliance is not an administrative goal, but the foundation of trust in the market.”
With the entry into force of Regulation (EU) 2017/745(MDR), the medical device industry has undergone one of the most profound regulatory changes in decades. For Swiss companies-manufacturers, importers, and distributors-implementation of the MDR poses a particular challenge, especially after the failure to sign the Institutional Framework Agreement between Switzerland and the EU, which led to the absence of the updated Mutual Recognition Agreement (MRA).
In this new scenario, understanding the practical implications of MDR is essential to remain competitive, ensure compliance and preserve access to the European market.
MDR: what changes for Switzerland
As of May 26, 2021, with the full entry into force of the MDR, Switzerland officially became a third country to the EU. This has led to important consequences:
1. End of automatic recognition of compliance
Mutual recognition of conformity assessments between CH and EU is no longer automatic.
Swiss companies must therefore adapt to the requirements for economic operators from third countries.
2. Mandatory introduction of the figure of the EU Importer
To export devices to the European market, a Swiss manufacturer must appoint an importer established in the EU with responsibilities defined by the MDR.
3. Need for a European Representative (EC-REP).
For Swiss manufacturers, the designation of an EU authorized representative is mandatory to place devices on the European market.
4. Updated labeling and traceability
They must appear on packaging and documents:
- EU importer data
- data of the EU representative
- UDI compliant MDR
5. Additional requirements in Switzerland
As the bilateral framework is no longer fully recognized, Switzerland has introduced transitional measures and autonomous requirements through the revision of theMedical Devices Ordinance (MCOD), imposing:
- Swiss Authorized Representative (CH-REP) requirement for EU/extra-EU manufacturers
- registrations with Swissmedic
- Surveillance, supervision and traceability requirements parallel to those in Europe
Summary Table: MDR Switzerland – Impacts for Economic Operators
| Economic operator | Relevant MDR requirements | Specific implications for Switzerland |
|---|---|---|
| Swiss manufacturer | MDR compliance, UDI, post-market surveillance, clinical evaluation | Appointment EU Importer + EU Representative; CH-REP requirements for Swiss market if manufacturer is not established in CH |
| Swiss importer | Pre-market compliance verification, label control, UDI | If importing into CH from EU/extra EU: foreign manufacturer’s CH-REP requirement; documentary responsibilities with Swissmedic |
| Swiss distributor | Controls provided by MDR (storage, traceability, labeling) | Similar duties to EU distributors + ODMed requirements for the Swiss market |
| EU / non-EU manufacturer selling in CH | N/A on the internal MDR side | Obligation to appoint a CH-REP and register with Swissmedic |
Operational impact: what Swiss companies need to do today
1. Adapt the structure of economic operators
Companies need to update roles and contracts to include:
- EU Representative (EC-REP)
- EU Importer
- CH-REP (if applicable)
Each actor must have documented tasks, responsibilities and information flows.
2. Update the technical documentation
The MDR requires a more detailed Technical Documentation, with:
- enhanced clinical evaluations
- more robust scientific evidence
- More demanding biocompatibility controls
- More stringent requirements for software and digital devices
3. Strengthen the post-market surveillance system (PMS).
Companies need to implement:
- PMS and PMCF (Post-Market Clinical Follow-Up).
- trend reporting
- Systematic analysis of accidents and near misses
4. Review the supply chain
It is necessary to ensure:
- Clear agreements with importers/distributors
- compliance in storage and transportation practices
- UDI traceability throughout the chain
5. Implement stronger regulatory governance
The MDR requires companies to have an internal competent figure: the Person Responsible for Regulatory Compliance (PRRC).
Opportunities: not just obligations
Although MDR compliance may seem onerous, it can become a competitive advantage for Swiss companies:
- Greater perceived reliability
Being compliant with the most demanding European standards enhances reputation. - Stable access to EU and global markets
MDR compliance is increasingly recognized as an international benchmark. - Digitization and more efficient processes
The transition is forcing many companies to optimize documentation, PMS and quality. - Reducing legal and operational risks
Clear chains of responsibility and advanced traceability reduce costs and accidents.
Conclusion
Implementing the MDR in a context where Switzerland is considered a third country requires companies to deeply review their organization, responsibilities and processes.
For manufacturers, importers and distributors, this is not just a document update, but a real strategic realignment to ensure market access, device safety and international competitiveness.
In an ever-changing industry, compliance is not a constraint-it is an investment that protects the business and strengthens the confidence of users and authorities.